Numbers of recurrences on each dose of ranitidine, and in smokers and non-smokers were compared using Fisher's exact test. Cumulative recurrence rates were calculated using the product limit life table method. Patients who were withdrawn from the study for reasons other than ulcer relapses were included in analysis up to the time of the last valid endoscopic examination. Differences were deemed statistically significant if p was less than 0.05 for a two tailed test.
Patients and methods
The study was Figure) In patients receiving ranitidine 300 mg at night, however, recurrence rates were similar in smokers and non-smokers throughout the period of the study (Table IV and Figure) . Thus, increasing the maintenance dose of ranitidine to 300 mg at night abolished the adverse effect of cigarette smoking that was observed during maintenance with ranitidine 150 mg. [ Smoker taking ranitidine 150mg
Non-smokers taking ranitidine 150mg A proportion of patients still relapse, however, on standard maintenance treatment and full dose maintenance therapy has been recommended for these.6 In the present study recurrence rates during treatment with ranitidine 300 mg at night were approximately halfthose during treatment with ranitidine 150 mg. Two previously reported studies failed to show a therapeutic benefit from increasing the standard maintenance dose of cimetidine or famotidine in duodenal ulcer disease. A multicentre coml~~~~~1 m Maintenance treatment ofduodenal ulceration: ranitidine 300 mg at night is better than 150 mg in cigarette smokers 153 parison of cimetidine 400 mg with 800 mg showed that symptomatic recurrence rates during treatment with either dose of cimetidine were similar (17% and 15% respectively at one year) but that asymptomatic recurrences were more frequent in patients receiving the higher dose of cimetidine (10% and 16% respectively).7 Similarly, in a study comparing famotidine 20 mg with famotidine 40 mg, recurrence rates were 23% and 25% respectively after one year.8 A study comparing ranitidine 150 mg at night with ranitidine 150 mg twice daily in the maintenance of duodenal ulcer healing showed, however, that recurrence rates were reduced from 27% to 17% at one year by the higher dose of ranitidine. 9 It has previously been reported that recurrence during maintenance treatment is more common in smokers than in non-smokers.410 This may relate to an adverse effect on plasma concentration of orally administered ranitidine in cigarette smokers." In the present study 83% of all recurrences were in smokers. The relative risk for ulcer recurrence was statistically significantly greater in smokers than in non-smokers receiving ranitidine 150 mg at night. In patients receiving ranitidine 300 mg at night, however, the recurrence rates were similar in smokers and non-smokers. This suggests that the reduction in recurrence rates during maintenance treatment with ranitidine 300 mg was attributable to a specific therapeutic benefit of the higher dose in cigarette smokers, although the possibility of a type I error cannot be entirely excluded. The results of the present study indicate that in patients who relapse during standard dose maintenance therapy and who are smokers (the majority), maintenance treatment with ranitidine 300 mg at night is an effective and safe therapeutic option to reduce the risk of further recurrence. 
